Insider Selling: Henry Schein (NASDAQ:HSIC) CEO Sells 38,346 Shares of Stock

Henry Schein, Inc. (NASDAQ:HSIC) CEO Stanley Bergman sold 38,346 shares of the firm’s stock in a transaction that occurred on Thursday, February 26th. The stock was sold at an average price of $81.01, for a total transaction of $3,106,409.46. Following the completion of the transaction, the chief executive officer directly owned 427,615 shares of the company’s stock, valued at approximately $34,641,091.15. This trade represents a 8.23% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which is available through the SEC website.

Henry Schein Stock Performance

HSIC stock traded up $0.92 during midday trading on Friday, reaching $82.39. 1,562,469 shares of the company’s stock traded hands, compared to its average volume of 1,447,010. The firm has a market capitalization of $9.70 billion, a PE ratio of 25.20, a price-to-earnings-growth ratio of 2.43 and a beta of 0.88. The company has a 50-day moving average price of $77.75 and a two-hundred day moving average price of $72.04. Henry Schein, Inc. has a 52 week low of $60.56 and a 52 week high of $89.29. The company has a debt-to-equity ratio of 0.59, a quick ratio of 0.79 and a current ratio of 1.38.

Henry Schein (NASDAQ:HSIC) last announced its quarterly earnings results on Tuesday, February 24th. The company reported $1.34 earnings per share for the quarter, beating the consensus estimate of $1.30 by $0.04. The company had revenue of $3.44 billion during the quarter, compared to analysts’ expectations of $3.34 billion. Henry Schein had a return on equity of 15.16% and a net margin of 3.02%.The firm’s quarterly revenue was up 7.7% compared to the same quarter last year. During the same period in the previous year, the business earned $1.19 earnings per share. Henry Schein has set its FY 2026 guidance at 5.230-5.370 EPS. As a group, equities analysts anticipate that Henry Schein, Inc. will post 4.74 EPS for the current year.

Institutional Investors Weigh In On Henry Schein

Hedge funds and other institutional investors have recently modified their holdings of the stock. CYBER HORNET ETFs LLC purchased a new position in Henry Schein in the 2nd quarter worth approximately $25,000. MUFG Securities EMEA plc purchased a new stake in Henry Schein during the 2nd quarter valued at $27,000. Flagship Harbor Advisors LLC bought a new stake in Henry Schein in the 4th quarter worth $30,000. Federated Hermes Inc. bought a new position in shares of Henry Schein during the fourth quarter valued at about $32,000. Finally, Los Angeles Capital Management LLC bought a new stake in shares of Henry Schein in the fourth quarter worth about $37,000. Institutional investors own 96.62% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have commented on HSIC shares. UBS Group raised their price target on shares of Henry Schein from $79.00 to $87.00 and gave the company a “neutral” rating in a report on Wednesday. Barrington Research set a $97.00 price target on Henry Schein and gave the company an “outperform” rating in a report on Wednesday. Wall Street Zen upgraded shares of Henry Schein from a “hold” rating to a “buy” rating in a research report on Saturday, November 8th. Leerink Partners lifted their target price on shares of Henry Schein from $75.00 to $87.00 and gave the company a “market perform” rating in a research report on Tuesday. Finally, Wells Fargo & Company increased their price target on shares of Henry Schein from $76.00 to $87.00 and gave the stock an “equal weight” rating in a report on Wednesday. Six equities research analysts have rated the stock with a Buy rating, six have issued a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $85.58.

Henry Schein Company Profile

Henry Schein, Inc is a leading global distributor of healthcare products and services, primarily serving office-based dental, medical and animal health practitioners. The company operates through three principal segments—Schein Dental, Schein Medical and Animal Health—each offering a comprehensive portfolio of consumable products, equipment, instruments and related value-added services. With a focus on improving practice efficiency and patient care, Henry Schein provides everything from dental restorative materials and orthodontic appliances to vaccines, pharmaceuticals and diagnostic devices for physicians, as well as pet health products and veterinary equipment for animal health professionals.

In addition to its broad product offering, Henry Schein delivers a suite of technology and service solutions aimed at streamlining workflows and enhancing clinical outcomes.